Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.36 |
| ▸ | MET | P08581 | 6/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155952 | 0.94 | TGFBR1 (0.39) | TGFBR1GRIN1GRIN2BMETCYP2C9 | |
| SCHEMBL25085092 | 0.93 | MET (0.39) | TGFBR1METCYP2C9PDE3BPDE3A | |
| SCHEMBL25084521 | 0.91 | TGFBR1 (0.39) | TGFBR1GRIN1GRIN2BMETCYP2C9 | |
| SCHEMBL25084614 | 0.87 | MET (0.39) | TGFBR1METCYP2C9PDE3BPDE3A | |
| SCHEMBL23389658 | 0.85 | MET (0.37) | TGFBR1METPDE3BPDE3A | |
| SCHEMBL29796697 | 0.85 | MET (0.37) | TGFBR1METPDE3BPDE3A | |
| SCHEMBL22075039 | 0.84 | GRIN2B (0.40) | GRIN1GRIN2BMET | |
| SCHEMBL30579117 | 0.84 | GRIN2B (0.40) | GRIN1GRIN2BMET | |
| SCHEMBL25085078 | 0.83 | TGFBR1 (0.37) | TGFBR1MET | |
| SCHEMBL23408254 | 0.81 | TGFBR1 (0.42) | TGFBR1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885GRIN1 2693/4885GRIN2B 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.